The Pancreatic Cancer Specialty Clinic (PCSC) defines a new standard of care for people with pancreatic cancer or pancreatic neuroendocrine tumors (NETs) and seeks to minimize the obstacles that patients and their families may encounter in navigating a complex medical system.
The PCSC has a dedicated team of surgical, medical, and radiation oncologists, radiologists, and pathologists, as well as nurses, symptom management and pain specialists, nutritionists, physical therapists, and social workers, all singularly devoted to the clinic’s mission.
One reason why pancreas cancer is so difficult to treat is that it's hard to get chemotherapy drugs into the cancer cells themselves. This resistance is due in part to a biological barrier the tumor builds around itself. Several years ago SCCA's Dr. Sunil Hingorani and his research team found a way to dissolve this barrier with an enzyme known as PEGPH20. This research has led to a series of clinical trials combining PEGPH20 with cancer drugs (chemotherapy) to treat pancreas cancer—so far the results have been promising.
SCCA is currently enrolling patients in two studies testing this approach, Modified FOLFIRINOX + PEGPH20 for Pancreatic Cancer (S1313) and PEGPH20 + Nab-Paclitaxel Plus Gemcitabine for Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma. Click on the trial links for more information.
SCCA was formed, in part, to bring promising new treatments to patients faster. For people with pancreatic cancer, this may mean more treatment options at SCCA than you might find elsewhere, including the chance to participate in clinical trials conducted at SCCA and its partner organizations, Fred Hutch and UW Medicine.